Gilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) combining compounds from each of their pipelines, including Novo
Novo Nordisk continues to build a case for its oral semaglutide GLP-1 class diabetes drug, with latest results from a phase 3a trial showing it is more effective than placebo at reducing bl
Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.
